ExpreS2ion provides update on anticipated development of the breast cancer vaccine candidate AV001, including a probable change in its ownership stake in AdaptVac
Hørsholm, Denmark, August 18, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces that ExpreS2ion wishes to exercise the option to inlicense AV001 before it expires on February 26, 2021. The exercise of the option is subject to the Company obtaining the necessary financing to fund the exercise of the option and the further preclinical development of AV001. If so, the Company expects to be able to submit an application to start clinical trials in the first half of 2022. The Company furthermore announces that it will transfer 16 percent of its joint venture